Skip to main content

The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review

Abstract

Background Anthracycline agents are known to be effective in treating tumors and hematological malignancies. Although these agents improve survival, their use is associated with cardiotoxic effects, which most commonly manifests as left ventricular systolic dysfunction (LVSD). As such, guidelines recommend the periodic assessment of left ventricular ejection fraction (LVEF). However, as diastolic dysfunction likely proceeds systolic impairment in this setting, the role of Tei index may offer additional benefit in detecting subclinical LVSD.

Methods We conducted a systematic review to investigate the evidence for the use of Tei index in assessing subclinical cardiotoxicity in patients receiving anticancer agents. A search of Medline and EMBASE was performed and relevant studies were reviewed and narratively synthesized.

Results A total of 13 studies were included with a total of 800 patients (mean age range 46-62 years, percentage of male participants ranged from 0-86.9%). An increase in Tei index was observed in 11 studies, which suggested a decline in cardiac function following chemotherapy. Out of these, six studies indicated that the Tei index is a useful parameter in predicting cardiotoxic LVSD. Furthermore, five studies indicated Tei index to be superior to LVEF in detecting subclinical cardiotoxicity.

Conclusions Though there are some studies that suggest that Tei index may be a useful indicator in assessing subclinical anthracycline-related cardiotoxicity, the findings are inconsistent and so more studies are needed before the evaluation of Tei index is performed routinely in patients receiving chemotherapy.

Conclusions Though there are some studies that suggest that Tei index may be a useful indicator in assessing subclinical anthracycline-related cardiotoxicity, the findings are inconsistent and so more studies are needed before the evaluation of Tei index is performed routinely in patients receiving chemotherapy.

References

  1. Dodos F, Halbsguth T, Erdman E & Hoppe UC Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clinical Research in Cardiology 2008 97 318–326. (https://doi.org/10.1007/s00392-007-0633-6)

    Article  Google Scholar 

  2. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN & Goodwin JS Decline in the use of anthracyclines for breast cancer. Journal of Clinical Oncology 2012 30 2232–2239. (https://doi.org/10.1200/JCO.2011.40.1273)

    Article  CAS  Google Scholar 

  3. Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. British Journal of Haematology 2015 170 85–95. (https://doi.org/10.1111/bjh.13399)

    Article  CAS  Google Scholar 

  4. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, et al. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 2016 122 3145–3151. (https://doi.org/10.1002/cncr.30173)

    Article  CAS  Google Scholar 

  5. Chung R, Ghosh AK & Banerjee A Cardiotoxicity: precision medicine with imprecise definitions. Open Heart 2018 5 e000774. (https://doi.org/10.1136/openhrt-2018-000774)

    Article  Google Scholar 

  6. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. American Journal of Cardiology 2011 107 1375–1380. (https://doi.org/10.1016/j.amjcard.2011.01.006)

    Article  CAS  Google Scholar 

  7. Zamorano JL, Lancelloti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspies of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal 2016 37 2768–2801.(https://doi.org/10.1093/eurheartj/ehw211)

    Article  Google Scholar 

  8. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging 2015 16 233–270. (https://doi.org/10.1093/ehjci/jev014)

    Article  Google Scholar 

  9. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P & Brunotte F Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment 2011 130 845–854. (https://doi.org/10.1007/s10549-011-1714-9)

    Article  CAS  Google Scholar 

  10. Cikes M & Solomon SD Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. European Heart Journal 2016 37 1642–1650. (https://doi.org/10.1093/eurheartj/ehv510)

    Article  Google Scholar 

  11. Patel CD, Balakrishnan VB, Kumar L, Naswa N & Malhotra A Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline cardiotoxicity? Hellenic Journal of Nuclear Medicine 2010 13 233–237.

    PubMed  Google Scholar 

  12. Goroshi M & Chand D Myocardial performance index (Tei index): a simple tool to identify cardiac dysfunction in patients with diabetes mellitus. Indian Heart Journal 2016 68 83–87. (https://doi.org/10.1016/j.ihj.2015.06.022)

    Article  Google Scholar 

  13. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ & Seward JB New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. Journal of Cardiology 1995 26 357–366.

    CAS  PubMed  Google Scholar 

  14. Ayhan SS, Ozdemir K, Kayrak M, Bacaksiz A, Vatankulu MA, Eren Ö, Koc F, Duman C, Gülec H, Demir K, et al. The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler dervied myocardial performance index. Cardiology Journal 2012 19 363–368. (https://doi.org/10.5603/cj.2012.0066)

    Article  Google Scholar 

  15. Belham M, Kruger A, Mepham S, Faganello G & Pritchard C Monitoring left ventricular function in adults receiving anthracycling-containing chemotherapy. European Journal of Heart Failure 2007 9 409–414. (https://doi.org/10.1016/j.ejheart.2006.09.007)

    Article  CAS  Google Scholar 

  16. Rohde LE, Baldi A, Weber C, Geib G, Mazzotti NG, Fiorentini M, Roggia M, Pereira R & Clausell N Tei index in adult patients submitted to Adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity. International Journal of Cardiovascular Imaging 2007 23 185–191. (https://doi.org/10.1007/s10554-006-9145-0)

    Article  Google Scholar 

  17. Di Lisi D, Bonura F, Macaione F, Peritore A, Meschisi M, Cuttitta F & Novo G, D’Alessandro N, Novo S Chemotherapy-induced cardiotoxicity: role of tissue Doppler in the early diagnosis of left ventricular dysfunction. Anti-Cancer Drugs 2011 22 468–472. (https://doi.org/10.1097/CAD.0b013e3283443704)

    Article  Google Scholar 

  18. Dogru A, Cabuk D, Sahin T, Dolasik I, Temiz S & Uygun K Evaluation of cardiotoxicity via speckle tracking echocardiography in patients treated with anthracyclines. Onkologie 2013 36 712–716. (https://doi.org/10.1159/000356850)

    CAS  PubMed  Google Scholar 

  19. Elalouani C, Benhmidoun MA, Rida H, AitRaiss M, Derhem N, Elomrani A, Khouchani M, Tahri A, Errehmouni A, Faouzi R, et al. Short and medium term cardiotoxicity of anthracyclins: a prospective study. Annales de Cardiologie et d’Angeiologie 2012 6 254–266.(https://doi.org/10.1016/j.ancard.2012.03.004)

    Google Scholar 

  20. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Navratil M, Pospisil Z & Vorlicek J Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin’s lymphoma. Neoplasma 2006 53 174–181.

    CAS  PubMed  Google Scholar 

  21. Erdoğan D, Yücel H, Alanoğlu EG, Uysal BA, Koçer M, Ozaydın M & Doğan A Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Turk Kardiyoloji Dernegi Arsivi 2011 39 646–653. (https://doi.org/10.5543/tkda.2011.01700)

    Article  Google Scholar 

  22. Mizia-Stec K, Gościńska A, Mizia M, Haberka M, Chmiel A, Poborski W & Gąsior Z Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodeling. Kardiologia Polska 2013 71 681–690. (https://doi.org/10.5603/KP.2013.0154)

    Article  Google Scholar 

  23. Senju N, Ikeda S, Koga S, Miyahara Y, Tsukasaki K, Tomonaga M & Kohno S The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart and Vessels 2007 22 393–397. (https://doi.org/10.1007/s00380-007-0985-x)

    Article  Google Scholar 

  24. Shaikh AY, Suryadevara S, Tripathi A, Ahmed M, Kane JL, Escobar J, Cerny J, Nath R, McManus DD, Shih J, et al. Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia - a velocity vector imaging analysis. Echocardiography 2016 33 1166–1177. (https://doi.org/10.1111/echo.13245)

    Article  Google Scholar 

  25. Billingham M & Bristow M Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treatment and Symptoms 1984 3 71–76.

    Google Scholar 

  26. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM & Kupersmith J Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. Journal of the American College of Cardiology 1992 20 62–69. (https://doi.org/10.1016/0735-1097(9290138-d)

    Article  CAS  Google Scholar 

  27. Mercuro G, Cadeddu C, Piras A, Dessì M, Madeddu C, Deidda M, Serpe R, Massa E & Mantovani G Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007 12 1124–1133. (https://doi.org/10.1634/theoncologist.12-9-1124)

    Article  CAS  Google Scholar 

  28. Møller JE, Sondergaard E, Poulsen SH & Egstrup E The Doppler echocardiographic myocardial performance index predicts left-ventricular dilation and cardiac death after myocardial infarction. Cardiology 2001 92 105–111.(https://doi.org/10.1159/000047355)

    Article  Google Scholar 

  29. Oikonomou EK, Kikkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D & Thavendiranathan P Assessment of prognostic valve od left ventricular global longitudinal strain for early prediction of chemotherapy induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiology 2019 4 1007–1018. (https://doi.org/10.1001/jamacardio.2019.2952)

    Article  Google Scholar 

  30. Zhang CJ, Pei XL, Song FY, Guo Y, Zhang QL, Shu XH, Hsi DH & Cheng LLC Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT. Echocardiography 2017 34 1593–1600. (https://doi.org/10.1111/echo.13704)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sadie Bennett.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articles Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articles Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bennett, S., Cubukcu, A., Wong, C.W. et al. The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review. Echo Res Pract 8, R1–R11 (2021). https://doi.org/10.1530/ERP-20-0013

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1530/ERP-20-0013

Key Words